<DOC>
	<DOC>NCT00485550</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of atomoxetine alone versus atomoxetine plus low-dose, sustained-release MPH in children with treatment-resistant ADHD.</brief_summary>
	<brief_title>Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Patients will be at least 6 years of age and not more than 12 years of age at visit 1 Patients must meet DSMIV diagnostic criteria for ADHD Patients must be retrospectively identified as stimulant nonresponders Patients must be of normal intelligence as assessed by the investigator (that is, without a general impairment of intelligence and likely, in the investigator's judgment, to achieve a score of greater than or equal to 70 on an IQ test) Patients must be able to swallow capsules Patients who weigh less than 22 kg or more than 60 kg at study entry Patients who have a history of Bipolar I or Bipolar II Disorder, psychosis, or pervasive developmental disorder Patients who meet DSMIV criteria for anxiety disorder or autism Patients with a history of any seizure disorder and/or Rolandic seizures (other than febrile seizures) or prior electroencephalogram (ECG) abnormalities in the absence of seizures, or patients who have taken (or are currently taking) anticonvulsants for seizure control Patients with a history of severe allergies to more than one class of medication or multiple adverse drug reactions, including hypersensitivity to MPH</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>